Pfizer, Merck, Eli Lilly, AbbVie and Bristol Myers Squibb are among US drugmakers striking multibillion-dollar deals to source experimental medicines from China, according to a report. The trend signals a shift in pharmaceutical R&D sourcing toward Chinese biotech firms.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
